WuXi Biologics (Cayman) Inc
HKEX:2269
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
10.26
46.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
WuXi Biologics (Cayman) Inc
WuXi Biologics (Cayman) Inc
Gross Profit
WuXi Biologics (Cayman) Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Gross Profit
¥6.6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Gross Profit
¥15.4B
|
CAGR 3-Years
27%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Gross Profit
¥3.8B
|
CAGR 3-Years
19%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Gross Profit
¥2.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
15%
|
CAGR 10-Years
26%
|
|
|
M
|
MGI Tech Co Ltd
SSE:688114
|
Gross Profit
¥1.5B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Gross Profit
¥559.6m
|
CAGR 3-Years
310%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
WuXi Biologics (Cayman) Inc
Glance View
WuXi Biologics (Cayman) Inc. is a leading global provider of biologics development and manufacturing solutions, operating at the intersection of healthcare innovation and advanced biotechnology. Founded in 2010, the company has rapidly transformed from a local player into a dominant force that serves pharma and biotech firms worldwide. WuXi Biologics offers a comprehensive suite of services, including cell line development, process development, clinical manufacturing, and commercial production of biologics, helping its partners bring life-saving therapies to market with speed and efficiency. With a robust pipeline of collaborations and a commitment to excellence, WuXi is strategically positioned to capitalize on the growing demand for biologics, particularly in the realms of monoclonal antibodies and gene therapies. For investors, WuXi Biologics represents a compelling opportunity in the rapidly evolving biopharmaceutical landscape. The company’s expansive global network, which includes state-of-the-art facilities in China, Europe, and the United States, allows it to meet rising demand while maintaining high-quality standards. WuXi is well-supported by a solid financial foundation, marked by impressive revenue growth and a strong balance sheet. As regulatory frameworks become more favorable and the biopharma industry continues to innovate, WuXi Biologics stands poised to drive sustainable long-term growth, making it an appealing consideration for investors looking to tap into the promising future of medical therapies.
See Also
What is WuXi Biologics (Cayman) Inc's Gross Profit?
Gross Profit
6.6B
CNY
Based on the financial report for Jun 30, 2024, WuXi Biologics (Cayman) Inc's Gross Profit amounts to 6.6B CNY.
What is WuXi Biologics (Cayman) Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
39%
Over the last year, the Gross Profit growth was -4%. The average annual Gross Profit growth rates for WuXi Biologics (Cayman) Inc have been 18% over the past three years , 39% over the past five years .
You don't have any saved screeners yet
